Evidence map›Paper›PMID 30718938›Full record

ArticleAerosol science and technology : the journal of the American Association for Aerosol Research2018

Generation of High Concentrations of Respirable Solid-Phase Aerosols from Viscous Fluids.

Xin Heng, Donovan B Yeates

Abstract read
In one paragraph

Article in Aerosol science and technology : the journal of the American Association for Aerosol Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Xin HengKAER Biotherapeutics, 926 Andreasen Drive, Suite 105, Escondido, California, USA.
Donovan B YeatesKAER Biotherapeutics, 926 Andreasen Drive, Suite 105, Escondido, California, USA.ORCID https://orcid.org/0000-0002-7771-068X

Funding

Aerosol Delivery of Surfactant for ARDSR44HL127834 · NHLBI · KAER BIOTHERAPEUTICS CORPORATION · PI YEATES, DONOVAN BYRON · 2018 to 2019
$2.0M
SUPRAER, High Dose Rate Aerosol Drug DeliveryR44HL078281 · NHLBI · BIOTECHPLEX CORPORATION · PI YEATES, DONOVAN B · 2007 to 2008
$879k
Aerosol Delivery of Surfactant for ARDSR43HL127834 · NHLBI · KAER BIOTHERAPEUTICS CORPORATION · PI YEATES, DONOVAN BYRON · 2015 to 2015
$291k
NHLBI NIH HHS R43 HL127834NHLBI NIH HHS R44 HL078281NHLBI NIH HHS R44 HL127834
6 · The paper itself

Abstract

High outputs of respirable solid-phase aerosols were generated from viscous solutions or suspensions of low and high molecular weight polyvinylprrolidone (PVP) solutions, 10% (w/v) albumin and, gamma-globulin solutions as well as 10.3% (w/v) surfactant suspensions. A central fluid flow was aerosolized by coaxial converging compressed air. The water was evaporated from the droplets using warm dilution air and infrared radiation. The resulting aerosol particles were concentrated using a virtual impactor. The aerosols were generated at fluid flow rates between 1 and 3 ml/min and delivered at a flow rate of 44 l/min as 2.6 - 3.6 μm MMAD aerosols with geometric standard deviations between 1.5 and 2. Increases in viscosity over the range of 4 to 39 cSt caused a modest increase in MMAD. Increases in aerosol exit orifice diameter was associated with a decrease in aerosol diameter. Increases in compressed air pressure caused a decrease in aerosol diameter. Increases in fluid flow rate resulted modest increases in MMAD together with proportional increases in output mass. Aerosolizing 10% 8 kDa PVP at 3 ml/min resulted in the delivery of 193 mg/min of PVP at 64% efficiency enabling 1.2 g to be collected in 7 min. Aerosolizing 10.3% surfactant suspensions at 3 ml/min resulted in the delivery of up to 163 mg/min with 59% efficiency. The surface tension of the surfactant was not changed by these processes. SEM showed dimpled particles of PVP, albumin and gamma globulin indicating that their aerodynamic diameter was less than their morphometric diameter.

Indexed as

aerosol drug deliveryantibodiesARDSmacromoleculesproteinsspray dryingsurfactant

Identifiers

PMID30718938
PMCPMC6358172

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.